China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD 323 million) for the third quarter of 2024, marking a 40% year-on-year (YOY) increase. The company’s competitive edge in China is attributed to its product indication expansion, extensive coverage on the National Reimbursement Drug List, and access channel strategies. During the quarter, the PD-1 inhibitor Tyvyt (sintilimab injection) maintained strong market performance, and there was a notable increase in uptake for Innovent’s other products.
Currently, Innovent has 11 products approved for marketing, with 5 under marketing review by the National Medical Products Administration in China. The company has 3 products in Phase III or pivotal clinical stages and 17 in clinical trials. The recent approval of fulzerasib in China for the treatment of KRAS G12C mutant advanced non-small cell lung cancer (NSCLC) highlights the company’s more comprehensive pipeline portfolio and a more mature workforce in the lung cancer mutation treatment sector.- Flcube.com
